Drug intelligence / Profile preview

moxifloxacin + oseltamivir + piperacillin + tazobactam

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination of four drugs: moxifloxacin (a fluoroquinolone antibiotic), oseltamivir (an antiviral medication), and piperacillin-tazobactam (a combination penicillin antibiotic with a beta-lactamase inhibitor). Studies have shown synergistic bactericidal activity when moxifloxacin is combined with piperacillin-tazobactam against various gram-negative bacteria including Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii. The combination demonstrated enhanced bactericidal activity compared to either agent used alone.

Targets

Neuraminidaseβ-lactamaseTopo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)DNA gyrase

Beyond the preview

Go deeper on moxifloxacin + oseltamivir + piperacillin + tazobactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on moxifloxacin + oseltamivir + piperacillin + tazobactam.

Explore the full profile